Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025
Theravance Biopharma (NASDAQ: TBPH) has scheduled its second quarter 2025 financial results announcement and business update for August 12, 2025, after market close. The company will host a conference call and webcast at 5:00 pm ET on the same day.
Interested participants can pre-register for the telephone conference, while those preferring to listen via the internet can access the webcast through the company's website. A replay will be available for 30 days through September 11, 2025.
Theravance Biopharma (NASDAQ: TBPH) ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 e un aggiornamento aziendale per il 12 agosto 2025, dopo la chiusura dei mercati. La società terrà una teleconferenza e una diretta web alle 17:00 ET dello stesso giorno.
I partecipanti interessati possono preregistrarsi per la conferenza telefonica, mentre chi preferisce ascoltare via internet può accedere alla diretta streaming tramite il sito web dell'azienda. Una replica sarà disponibile per 30 giorni, fino all'11 settembre 2025.
Theravance Biopharma (NASDAQ: TBPH) ha programado el anuncio de los resultados financieros del segundo trimestre de 2025 y una actualización comercial para el 12 de agosto de 2025, después del cierre del mercado. La empresa realizará una llamada en conferencia y una transmisión en vivo a las 5:00 pm ET del mismo día.
Los participantes interesados pueden preregistrarse para la conferencia telefónica, mientras que quienes prefieran escuchar por internet pueden acceder a la transmisión en vivo a través del sitio web de la compañía. Una repetición estará disponible durante 30 días, hasta el 11 de septiembre de 2025.
Theravance Biopharma (NASDAQ: TBPH)는 2025년 2분기 재무 결과 발표 및 사업 업데이트를 2025년 8월 12일 장 마감 후에 예정했습니다. 회사는 같은 날 오후 5시 ET에 컨퍼런스 콜 및 웹캐스트를 진행할 예정입니다.
참석을 원하는 분들은 전화 컨퍼런스 사전 등록이 가능하며, 인터넷을 통해 듣기를 원하는 분들은 회사 웹사이트에서 웹캐스트에 접속할 수 있습니다. 녹화 방송은 30일간 2025년 9월 11일까지 제공됩니다.
Theravance Biopharma (NASDAQ : TBPH) a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 ainsi qu'une mise à jour commerciale pour le 12 août 2025, après la clôture du marché. La société organisera une conférence téléphonique et un webcast à 17h00 ET le même jour.
Les participants intéressés peuvent se préinscrire pour la conférence téléphonique, tandis que ceux qui préfèrent écouter via Internet peuvent accéder au webcast sur le site web de l'entreprise. Un replay sera disponible pendant 30 jours, jusqu'au 11 septembre 2025.
Theravance Biopharma (NASDAQ: TBPH) hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 und ein Geschäftsupdate für den 12. August 2025 nach Börsenschluss geplant. Das Unternehmen wird am selben Tag um 17:00 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten.
Interessierte Teilnehmer können sich vorab für die Telefonkonferenz registrieren, während diejenigen, die lieber über das Internet zuhören möchten, den Webcast über die Website des Unternehmens abrufen können. Eine Aufzeichnung wird für 30 Tage bis zum 11. September 2025 verfügbar sein.
- None.
- None.
Conference Call Information
To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by clicking here or visiting the Events and Presentation page under the Investors Section on Theravance Biopharma's website.
A replay of the webcast will be available on Theravance Biopharma's website for 30 days through September 11, 2025.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-second-quarter-2025-financial-results-on-august-12-2025-302514625.html
SOURCE Theravance Biopharma, Inc.
FAQ
When will Theravance Biopharma (TBPH) report Q2 2025 earnings?
What time is Theravance Biopharma's Q2 2025 earnings call?
How can investors access TBPH's Q2 2025 earnings call?
How long will TBPH's Q2 2025 earnings call replay be available?
